Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer

DISEASE CHARACTERISTICS:

* Diagnosis of one of the following hematopoietic malignancies:

  * Acute lymphoblastic leukemia or myeloid leukemia with \< 30% blasts in the bone marrow
  * Juvenile myelomonocytic leukemia
  * Chronic myelogenous leukemia in chronic or accelerated phase
  * Relapsed non-Hodgkin's or Hodgkin's lymphoma in at least partial remission
* Considered at high risk (\> 30%) of toxic death with standard hematopoietic stem cell transplantation (HSCT), as indicated by at least one of the following:

  * Creatinine \> 1.5 times normal OR creatinine clearance \< 70 mL/min OR tubular damage that is not corrected by cessation of chemotherapy
  * DLCO \< 60% of predicted OR history of prior intubation due to lung disease (intubation for surgery excluded)
  * Shortening fraction \< 30%
  * History of disseminated fungal infection during chemotherapy OR currently receiving antifungal agents OR history of ≥ 2 septic episodes (confirmed by cultures) that required ICU support

    * Patients with improving fungal or other infections eligible

      * Improving infection is defined as confirmed negative cultures on 2 separate occasions, at least 1 week apart, and/or stable or improving imaging studies (e.g., CT scan) of the infected site
      * Two imaging studies taken at least 2 weeks apart must show stable or improved disease
  * History of stroke or abnormal MRI/MRA OR leukoencephalopathy OR seizures that are not fully controlled with anticonvulsants (\> 2 episodes of seizures in the preceding year or 1 episode of status epilepticus in a patient who is receiving anticonvulsant therapy)
  * History of prior significant bleeding (e.g., pulmonary, CNS, or gastrointestinal) OR history of a clotting disorder as manifested by prior significant thromboses (e.g., superior vena cava, inferior vena cava, or femoral vein)
* Failed conventional therapies and not eligible for myeloablative protocols

  * May have failed prior conventional HSCT
* No active CNS leukemia
* Unrelated or related donor available, meeting the following criteria:

  * Matched for at least 7/8 loci by high-resolution typing
  * One mismatch at A, B, or C loci allowed
  * Fully matched at DRB1 locus

PATIENT CHARACTERISTICS:

* ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%
* No active/progressing viral, bacterial, protozoal, or fungal infection
* Transaminases ≤ 5 times normal (except in the presence of autoimmune liver disease)
* Shortening fraction ≥ 25%
* DLCO ≥ 40% OR pulse oximetry ≥ 85% on room air
* Glomerular filtration rate ≥ 40 mL/min

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* Prior prolonged intensive chemotherapy (\> 3 years of therapy or ≥ 3 different chemotherapeutic protocols) allowed